vibozilimod

Vibozilimod is a highly selective, orally available small molecule agonist of the sphingosine 1-phosphate receptor 1 (S1PR1), developed primarily for the treatment of moderate to severe plaque psoriasis and atopic dermatitis. By selectively activating S1PR1 (with over 10,000-fold selectivity versus S1PR3), vibozilimod induces internalization of this receptor on lymphocytes, preventing their egress from lymph nodes into peripheral circulation. This immunomodulatory mechanism reduces inflammation associated with autoimmune skin diseases. Vibozilimod was designed as a second-generation alternative to less selective first-generation agents like fingolimod and aimed to offer improved safety—particularly regarding cardiac side effects—over Janus kinase inhibitors and earlier S1P modulators. The drug was developed by Sun Pharma Advanced Research Company in collaboration with Bioprojet and Sun Pharmaceutical Industries. Despite promising pharmacodynamic effects in early studies (notably reduction in circulating lymphocyte counts), phase II trials for both psoriasis and atopic dermatitis failed to meet primary efficacy endpoints by mid-2025; as a result, further development has been discontinued[2][3][7][10].

Other names

1403232-33-60GYJ8CJ1DEVibozilimod [INN]1-((4-(5-(3-Chloro-4-(2-methylpropyl)phenyl)-1,2,4-oxadiazol-3-yl)phenyl)methyl)-4-((2-methoxyethoxy)methyl)-4-piperidinecarboxylic acid